BridgeBio Oncology Therapeutics (NASDAQ: BBOT) widens Q2 loss but extends cash runway
Rhea-AI Filing Summary
BridgeBio Oncology Therapeutics, Inc. reported second quarter 2026 results and provided an update on its RAS-pathway oncology pipeline. The company is advancing three wholly owned clinical programs: BBO-8520 (KRAS G12C inhibitor), BBO-11818 (pan-KRAS inhibitor targeting KRASG12D/V), and BBO-10203 (blocking RAS–PI3Kα interaction) in multiple monotherapy and combination cohorts, including combinations with pembrolizumab, cetuximab, tucatinib, trastuzumab and internal combinations of its own assets.
As of June 30, 2026, cash, cash equivalents and marketable securities totaled $344.1 million, which management expects to fund operations into 2028. Second quarter 2026 research and development expenses were $49.2 million and general and administrative expenses were $11.0 million, both higher than the prior-year quarter, reflecting increased clinical and manufacturing activity and the start of standalone, post–de-SPAC operations. Net loss for the quarter was $56.5 million, with an accumulated deficit of $455.1 million and total stockholders’ equity of $323.1 million.
Positive
- $344.1 million in cash, cash equivalents and marketable securities as of June 30, 2026, with stated cash runway expected to fund operations into 2028.
- Advancement of all three clinical programs, including initiation of multiple internal combination cohorts (BBO-8520 and BBO-11818 each combined with BBO-10203) and continued enrollment across oncology indications.
- Presentation of preclinical data at AACR showing potent activity of BBO-11818 in KRASG12D/V models and strong combination effects of BBO-10203 with HER2 inhibitors in HER2amp tumor models.
Negative
- Second quarter 2026 net loss increased to $56.5 million from $28.4 million a year earlier, driven by higher operating expenses.
- Research and development expenses rose to $49.2 million from $27.4 million year over year, reflecting significantly higher clinical and manufacturing spend.
- General and administrative expenses increased to $11.0 million from $2.7 million, including costs related to standalone operations, a de-SPAC transaction, and one-time severance.
- Cash, cash equivalents and marketable securities declined from $425.5 million at December 31, 2025 to $344.1 million at June 30, 2026, reflecting ongoing cash burn.
- Accumulated deficit widened to $455.1 million as of June 30, 2026, compared with $356.6 million at year-end 2025.
Filing Explained
Two internal combinations have entered patient dosing; June 30 cash and securities were $344.1 million versus $425,460 thousand at year-end.
Under Item 2.02, the company furnished second-quarter results and a business update; the material progression is that two internal drug combinations have moved into patient dosing, while no new ownership or dilution mechanics are disclosed.
Form 8-K reports specified material events, and this filing reports results for the quarter ended
These updates place those combinations in an initiated-dosing stage rather than a merely planned stage; the filing does not state that either combination is complete or approved.
At June 30, the balance sheet reported
The company’s stated cash runway into 2028 remains an expectation; the release identifies enrollment, trial design, safety, supply and cash sufficiency as uncertainties to track in later filings.
8-K Event Classification
Key Figures
Key Terms
RAS-pathway inhibitors medical
KRASG12C medical
PI3Kα-AKT signaling medical
de-SPAC transaction financial
HER2amp tumor models medical
transition services agreements financial
Earnings Snapshot
Management expects existing cash, cash equivalents and marketable securities to provide cash runway into 2028.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What were BridgeBio Oncology Therapeutics (BBOT) Q2 2026 R&D and G&A expenses?
What was BridgeBio Oncology Therapeutics (BBOT) Q2 2026 net loss?
How much cash does BBOT have and how long is its runway?
What are the key clinical programs BBOT is advancing?
Did BridgeBio Oncology Therapeutics (BBOT) provide any clinical or preclinical data updates?
What does the 8-K filing from BBOT on August 11, 2026 cover?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of Registrant as Specified in Its Charter)
|
|
|||
(State or Other Jurisdiction of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
(Address of principal executive offices, including zip code)
(Telephone number, including area code, of agent for service)
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02 Results of Operations and Financial Condition.
On August 11, 2026, BridgeBio Oncology Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2026. A copy of the press release is attached as Exhibit 99.1.
The information in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”) or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of the general incorporation language of such filing, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. |
|
Description |
|
|
|
99.1 |
|
Press release dated August 11, 2026. |
|
|
|
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
|
BRIDGEBIO ONCOLOGY THERAPEUTICS, INC. |
|
|
|
|
|
Date: August 11, 2026 |
|
By: |
|
/s/ Pedro J. Beltran |
|
|
Name: |
|
Pedro J. Beltran, Ph.D. |
|
|
Title: |
|
Chief Executive Officer |
Exhibit 99.1
BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
SOUTH SAN FRANCISCO, Calif., August 11, 2026 — BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today reported financial results for the second quarter ended June 30, 2026, and provided a business update.
BBOT’s portfolio of RAS-pathway inhibitors is designed to enable direct dual inhibition of KRASG12C (BBO-8520), or KRASG12D/V (BBO-11818) in both its ON and OFF states as well as disruption of RAS-driven PI3Kα activation (BBO-10203) to achieve optimal target coverage of the most mutated driver oncogene in human cancer. Together, these assets uniquely position BBOT to achieve concurrent, high-level suppression of both the MAPK and PI3Kα pathways through a wholly-owned internal combination strategy.
“During the second quarter, we made meaningful progress in patient enrollment in our monotherapy and combination cohorts across each of our three clinical programs. Differentiated patient benefit in oncology is driven by optimal target coverage and the ability to combine with standard-of-care regimens. Therefore, we continue to focus heavily on advancing our combination development strategies,” said Pedro J. Beltran, Ph.D., Chief Executive Officer of BBOT. “In addition, our wholly-owned portfolio is uniquely positioned to enable concurrent suppression of the MAPK and PI3Kα pathways through internal combination strategies of each of our KRAS inhibitors with BBO-10203. We are excited to have both combinations already underway in patients. With multiple near-term clinical milestones across all programs expected in the second half of 2026 and cash runway into 2028, we believe we are well positioned to execute our strategy and expand treatment options for patients with mutant KRAS-driven cancers.”
Key Program Highlights and Updates
BBO-8520: An orally bioavailable small molecule direct inhibitor targeting both the ON and OFF states of KRAS G12C.
BBO-11818: An orally bioavailable small molecule pan-KRAS inhibitor that targets mutant KRAS in both the ON and OFF states.
BBO-10203: An orally bioavailable small molecule with a novel mechanism of action designed to block the physical interaction between RAS and PI3Kα, inhibiting RAS-driven PI3Kα-AKT signaling in tumors.
Second Quarter 2026 Financial Results
About BBOT
BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, please visit www.bbotx.com and follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, and other federal securities laws. Any statements in this press release that are not historical facts may be deemed forward-looking statements, which generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends. These forward-looking statements include, without limitation, statements regarding the clinical and therapeutic potential and safety profile of BBOT’s product candidates, including BBO-8520, BBO-10203 and BBO-11818, as monotherapy or in combination with other therapeutics, the design and conduct of clinical trials with BBOT’s product candidates, including enrollment and dosing of ongoing clinical internal and external combination studies, and BBOT's beliefs, expectations and assumptions regarding the future of its business, future plans and strategies, including statements regarding anticipated operating expenses, BBOT’s cash runway and sufficiency of its cash and cash equivalents to fund its operations.
These statements are based on various assumptions, whether or not identified in this press release, and are the current expectations of BBOT’s management and are not predictions of actual performance. Many actual events and circumstances are beyond the control of BBOT. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political, and legal conditions; the design and success of ongoing and planned clinical trials; adverse events that may be encountered in BBOT’s clinical trials; risks relating to the uncertainty of the projected financial information with respect to BBOT; risks related to the preclinical and clinical development of BBOT’s product candidates, including BBO-8520, BBO-10203 and BBO-11818, and the timing of expected regulatory and business milestones, including the progress of enrollment in clinical trials and availability of data from ongoing and planned clinical trials; the impact of competitive products; risks relating to BBOT’s ability to obtain sufficient supply of materials; and those factors discussed in documents BBOT has filed or will file with the U.S. Securities and Exchange Commission.
In addition, forward-looking statements reflect BBOT’s expectations, plans, or forecasts of future events and views as of the date of this press release and are qualified in their entirety by reference to the cautionary statements herein. BBOT anticipates that subsequent events and developments will cause BBOT’s assessments to change. These forward-looking statements should not be relied upon as any guarantee, assurance, prediction or definitive statement of fact or probability or as representing BBOT’s assessments as of any date subsequent to the date of this press release. Neither BBOT, nor its affiliates undertake any obligation to update these forward-looking statements, except as required by law.
BBOT Contacts:
Investor Contact:
BBOT
Investors@BBOTx.com
Media Contact:
Inizio Evoke Comms
Jake.robison@inizioevoke.com
BridgeBio Oncology Therapeutics, Inc.
Condensed Consolidated Statements of Operations
(in thousands, except shares and per share amounts)
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
||||||||||
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||
Operating expenses: |
|
(unaudited) |
|
|
(unaudited) |
|
||||||||||
Research and development |
|
$ |
49,225 |
|
|
$ |
27,438 |
|
|
$ |
89,027 |
|
|
$ |
48,073 |
|
General and administrative |
|
|
10,962 |
|
|
|
2,655 |
|
|
|
17,339 |
|
|
|
5,157 |
|
Total operating expenses |
|
|
60,187 |
|
|
|
30,093 |
|
|
|
106,366 |
|
|
|
53,230 |
|
Loss from operations |
|
|
(60,187 |
) |
|
|
(30,093 |
) |
|
|
(106,366 |
) |
|
|
(53,230 |
) |
Other income, net: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Interest income |
|
|
3,551 |
|
|
|
1,666 |
|
|
|
7,495 |
|
|
|
3,475 |
|
Interest from transition services agreements |
|
|
196 |
|
|
|
— |
|
|
|
419 |
|
|
|
— |
|
Change in fair value of participation right liability |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(725 |
) |
Other income (expense) |
|
|
(14 |
) |
|
|
(8 |
) |
|
|
(108 |
) |
|
|
(10 |
) |
Total other income, net |
|
|
3,733 |
|
|
|
1,658 |
|
|
|
7,806 |
|
|
|
2,740 |
|
Net loss |
|
$ |
(56,454 |
) |
|
$ |
(28,435 |
) |
|
$ |
(98,560 |
) |
|
$ |
(50,490 |
) |
Net loss per share attributable to common stockholders, basic and diluted |
|
$ |
(705.20 |
) |
|
$ |
(566.46 |
) |
|
$ |
(1,230.89 |
) |
|
$ |
(1,168.26 |
) |
Weighted-average number of shares used in computing net loss per share attributable to common stockholders, basic and diluted |
|
|
80,054 |
|
|
|
50,198 |
|
|
|
80,072 |
|
|
|
43,218 |
|
Selected Condensed Consolidated Balance Sheet Data
(in thousands)
|
|
June 30, |
|
|
December 31, |
|
||
|
|
2026 |
|
|
2025 |
|
||
|
|
(unaudited) |
|
|
|
|
||
Cash and cash equivalents and marketable securities |
|
$ |
344,130 |
|
|
$ |
425,460 |
|
Total assets |
|
|
376,706 |
|
|
|
448,381 |
|
Total liabilities |
|
|
53,594 |
|
|
|
37,285 |
|
Accumulated deficit |
|
|
(455,127 |
) |
|
|
(356,567 |
) |
Total stockholders’ equity |
|
|
323,112 |
|
|
|
411,096 |
|